

**AMENDMENTS TO THE CLAIMS****CLAIMS 1-12 (CANCELLED)**

13. (New) A salt selected from the anhydrous and hydrated forms of (1R,2R,3S,5S)-2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane tartrate.

14. (New) The salt of claim 13 being selected from the anhydrous and hydrated forms of (1R,2R,3S,5S)-2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane L-tartrate.

15. (New) The salt of claim 13, being (1R,2R,3S,5S)-2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane L-tartrate monohydrate.

16. (New) The salt of claim 13, being an anhydrous form of (1R,2R,3S,5S)-2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane L-tartrate.

17. (New) The salt of claim 16, being the polymorphic form (form II) of (1R,2R,3S,5S)-2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane L-tartrate anhydrate characterized by the following principal peaks in its X-ray powder diffraction pattern:

Peak No.	1	2	3	4	5	6	7	8	9	10
2 Theta ° (Cu Kα)	10.35	11.68	12.53	14.81	15	15.77	16.82	17.41	17.77	18.87
d space (Å)	8.5	7.6	7.1	6.0	5.9	5.6	5.3	5.1	5.0	4.7
Peak	11	12	13	14	15	16	17	18	19	

2 Theta ° (Cu K $\alpha$ )	20.29	21.26	21.66	23.44	23.73	25.44	25.99	27.58	28.14	
d space (Å)	4.4	4.2	4.1	3.8	3.7	3.5	3.4	3.2	3.2	

18. (New) The salt of claim 16, being the polymorphic form (form III) of (1R,2R,3S,5S)-2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane L-tartrate anhydrate characterized by the following principal peaks in its X-ray powder diffraction pattern:

Peak No.	1	2	3	4	5	6	7	8	9	10
2 Theta ° (Cu K $\alpha$ )	5.37	10.6	10.82	11.58	11.88	12.79	14.78	16.27	16.5	17.03
d space (Å)	16.4	8.3	8.2	7.6	7.4	6.9	6.0	5.4	5.4	5.2
Peak	11	12	13	14	15	16	17	18	19	
2 Theta ° (Cu K $\alpha$ )	17.84	19.29	20.01	21.2	22.99	23.46	24.54	25.15	26.59	
d space (Å)	5.0	4.6	4.4	4.2	3.9	3.8	3.6	3.5	3.3	

19. (New) The salt of claim 16, being the polymorphic form (form IV) of (1R,2R,3S,5S)-2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane L-tartrate anhydrate characterized by the following principal peaks in its X-ray powder diffraction pattern:

Peak No.	1	2	3	4	5	6	7	8	9	10
2 Theta ° (Cu K $\alpha$ )	5.31	10.19	11.23	12.13	12.35	12.69	14.31	14.55	14.77	16.43
d space (Å)	16.6	8.7	7.9	7.3	7.2	7.0	6.2	6.1	6.0	5.4
Peak	11	12	13	14	15	16	17	18	19	20
2 Theta ° (Cu K $\alpha$ )	17.48	18.21	18.43	18.81	19.36	19.61	20.26	20.5	21.29	21.46
d space (Å)	5.1	4.9	4.8	4.7	4.6	4.5	4.4	4.3	4.2	4.1
Peak	21	22	23	24	25	26	27	28	29	30
2 Theta ° (Cu K $\alpha$ )	21.95	22.53	22.77	23.38	23.59	23.9	24.45	25.02	25.56	26.19

K $\alpha$ )										
d space (Å)	4.0	3.9	3.9	3.8	3.8	3.7	3.6	3.6	3.5	3.4
Peak	31	32								
2 Theta ° (Cu K $\alpha$ )	26.83	27.21								
d space (Å)	3.3	3.3								

20. (New) A pharmaceutical composition, comprising a therapeutically effective amount of a salt of claim 13, together with at least one pharmaceutically acceptable carrier, excipient or diluent.

21. (New) Use of a salt of claim 13 for the manufacture of a medicament.

22. (New) A method for treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a salt according to claim 13.

23. (New) The method according to claim 22, wherein the disease, disorder or condition is mood disorder, depression, atypical depression, depression secondary to pain, major depressive disorder, dysthymic disorder, bipolar disorder, bipolar I disorder, bipolar II disorder, cyclothymic disorder, mood disorder due to a general medical condition, substance-induced mood disorder, pseudodementia, Ganser's syndrome, obsessive compulsive disorder, panic disorder, panic

disorder without agoraphobia, panic disorder with agoraphobia, agoraphobia without history of panic disorder, panic attack, memory deficits, memory loss, attention deficit hyperactivity disorder, obesity, anxiety, generalized anxiety disorder, eating disorder, Parkinson's disease, parkinsonism, dementia, dementia of ageing, senile dementia, Alzheimer's disease, acquired immunodeficiency syndrome dementia complex, memory dysfunction in ageing, specific phobia, social phobia, post-traumatic stress disorder, acute stress disorder, drug addiction, drug abuse, cocaine abuse, nicotine abuse, tobacco abuse, alcohol addiction, alcoholism, pain, chronic pain, inflammatory pain, neuropathic pain, migraine pain, tension-type headache, chronic tension-type headache, pain associated with depression, fibromyalgia, arthritis, osteoarthritis, rheumatoid arthritis, back pain, cancer pain, irritable bowel pain, irritable bowel syndrome, post-operative pain, post-stroke pain, drug-induced neuropathy, diabetic neuropathy, sympathetically-maintained pain, trigeminal neuralgia, dental pain, myofacial pain, phantom-limb pain, bulimia, premenstrual syndrome, late luteal phase syndrome, post-traumatic syndrome, chronic fatigue syndrome, urinary incontinence, stress incontinence, urge incontinence, nocturnal incontinence, sexual dysfunction, premature ejaculation, erectile difficulty, erectile dysfunction, eating disorders, anorexia nervosa, sleep disorders, autism, mutism, trichotillomania, narcolepsy, post-stroke depression, stroke-induced brain damage, stroke-induced neuronal damage or Gilles de la Tourettes disease.